Research on the cell biology of tumors. Covers cancer-cell vulnerabilities, tumor spread, nanoreactor therapies, and AI-guided cancer research.
Researchers at Tel Aviv University have discovered a new cancer mechanism that prevents the immune system from attacking tumors. The discovery was made by reversing this mechanism, which stimulates the immune system to fight cancer cells, including those resistant to prevailing forms of immunotherapy.
Researchers developed a new imaging analysis technique combining biomarkers and tumor architecture to create a 'fingerprint' for each patient, enabling precise prognosis and treatment response. The method identified two previously undetected groups of patients, with exceptional good or bad prognoses.
Researchers have discovered key mutations in certain cancer cells that render WRN inhibitors ineffective. The study found that prolonged exposure to these inhibitors can lead to the acquisition of mutations in the WRN gene, allowing cancer cells to survive and develop resistance.
Researchers created a 3D-printed model to mimic the conditions that spur cancer cells' spread, allowing them to visualize this process in real-time. The model revealed a mechanism where low oxygen levels promote metastasis through lowering pH levels.
Researchers found that WNTinib significantly delayed tumour growth and extended survival in mice with hepatoblastoma cells harboring CTNNB1 mutations. The treatment also showed promise in shrinking tumors in patients' tumor tissue models, with some tumors disappearing completely.
Researchers at Van Andel Institute discovered that cutting off cancer cells' access to fat makes them highly sensitive to ferroptosis and drugs that induce it. This finding has promising implications for developing new anti-cancer strategies and potentially tailoring diets to enhance treatment effectiveness.
A new study has identified four categories of cancer mutations that cause drug resistance, providing targets for drug development and potential effective second-line therapies. The research highlights DNA changes that could be explored further to treat patients with specific genetic mutations.
A groundbreaking study has demonstrated the clinical success of a new nanoparticle-based, laser-guided therapy for prostate cancer treatment. The therapy successfully eliminated cancerous cells in 73% of patients after 12 months while preserving key functions and side effects.
Researchers have engineered probiotic bacteria to educate the immune system to destroy cancer cells, opening the door for a new class of cancer vaccines. The bacterial vaccine proved more efficacious than peptide-based therapeutic cancer vaccines in studies using mouse models of advanced colorectal and melanoma cancers.
A recent study published in Nature Cancer has discovered that cancer cells exhibit opposing pro and antitumor programs, with the former promoting metastasis and the latter combating tumor growth. This finding opens new avenues for therapeutic strategies to target highly aggressive and therapy-resistant tumors.
Scientists discovered a unique way in which yeast cells adapt to starvation by coating their mitochondria with massive molecular complexes called ribosomes. This adaptation has potential implications for cancer treatment as it may help overcome the challenges faced by cancer cells when they are starved of nutrients.
Researchers at Montefiore Einstein Comprehensive Cancer Center have discovered a natural immune mechanism in mice that stops escaped cancer cells from developing into tumors elsewhere in the body. Alveolar macrophages recognize and interact with disseminated cancer cells, producing signals that keep them dormant.
A new study found that 5-fluorouracil kills cells by interfering with RNA synthesis, not DNA damage. The findings suggest that combining 5-FU with drugs affecting RNA synthesis could make it more effective in patients with gastrointestinal cancers.
Researchers created the largest atlas of how tumor architecture changes in response to immune checkpoint therapy. The study found that multiple T cells recognize different neoantigens, altering the tumor ecosystem, and challenged prevailing theories on immunotherapy.
Researchers at ETH Zurich have found an antidepressant, vortioxetine, effective against glioblastomas, a particularly aggressive brain tumor with no cure. The drug's ability to cross the blood-brain barrier and trigger a signalling cascade makes it promising for treating this deadly tumour.
Researchers at Tel Aviv University discovered that aneuploid cells, which have an abnormal number of chromosomes, are more susceptible to certain types of anticancer drugs. The studies found that disrupting the MAPK pathway increases the sensitivity of these cancer cells to chemotherapy.
The University of Oklahoma Health Sciences has received a $5.3 million National Institutes of Health grant to support advanced cancer research in Oklahoma. The grant will help early-career researchers establish independently funded laboratories and build technology infrastructure specific to cancer investigations.
Researchers discover cancer cells rely on sphingolipids for immune evasion and signaling. The findings suggest targeting lipid production could enhance existing immunotherapies.
Researchers at WVU are working on a project to inhibit the myeloperoxidase enzyme, which feeds pancreatic cancer growth. By targeting this enzyme, they hope to boost the body's immune system to fight cancer, showing promise in mouse models and potential for future clinical trials.
Researchers at Aston University have created a potential treatment for bone cancer using gallium-doped bioactive glasses, which has shown a 99% success rate in killing osteosarcoma cells. The therapy also promotes early stages of bone formation and regenerates diseased bones.
Researchers propose a new approach to understanding cancer evolution, acknowledging the importance of environmental influences and epigenetic changes. By refining the clonal evolution model, they aim to develop more effective cancer therapies that consider the full complexity of cancer cell evolution.
Researchers have designed molecular 'cages' that selectively target and eliminate cancer cells in acidic microenvironments. The study, led by CSIC, proposes a new approach to overcome chemotherapy limitations, with potential for future ionophore development.
A new study from the CUNY Graduate Center uncovers key mechanisms responsible for the transformation of adult progenitor cells into brain tumors. Researchers found that a specific combination of genetic mutations and growth factor overproduction drives this transformation, highlighting the importance of epigenetic changes in glioma dev...
Researchers developed a new tool to track immune health patterns over time, revealing how checkpoint inhibitor therapies work together to recruit new T cells. The study found that the combination therapy produces waves of new T cells with each dose, rather than continually strengthening existing ones.
Researchers have developed a nanodrug that targets miR-10b, a small noncoding RNA implicated in cancer cell invasion and proliferation. The study shows that inhibiting miR-10b reduces the stemness of breast cancer cells, supporting dedifferentiation as a potential therapeutic mechanism.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
The LENN system protects and efficiently releases NA therapies within the cytoplasm of target cells, overcoming low efficiencies and immune system clearance issues. It is biomanufacturable, biodegradable, and highly tunable, targeting a variety of cells depending on their tumor-specific surface markers.
Researchers identified CYP2J2 as a key enzyme in austocystin D-mediated cytotoxicity. Overexpression of CYP2J2 enhanced cytotoxic effects, while depletion reduced sensitivity to austocystin D.
Researchers developed tumor cell-coated carbon nanohorns to deliver paclitaxel to colon cancer, exhibiting high accumulation at tumors and strong chemotherapeutic effects. The treatment also demonstrated a robust photothermal effect and immune responses, effectively destroying tumors.
Researchers have identified HLA-E as a critical negative regulator of NK cell interactions with cancer cells. Disrupting NKG2A:HLA-E interactions may stimulate both NK cell and cytotoxic T cell effector functions against cancer, offering a promising anti-cancer strategy.
A new study published in Nature Medicine shows that precision therapy can improve survival for men with metastatic castration-resistant prostate cancer. The treatment, which involves analyzing the genetic profile of the tumor, has been shown to be more effective than chemotherapy in patients whose tumors have specific mutations.
A new platform called CellTracksColab has been introduced to simplify cell tracking data analysis, enabling researchers to study cell movement and behavior. The tool provides a user-friendly interface for analyzing complex data, leading to new insights into diseases such as cancer metastasis.
Researchers developed a faster and more precise method to separate particles in fluids, enabling quicker sorting of cells in blood samples and removal of pollutants in water. The improved technique uses specially engineered channels and high polymer concentrations to guide particles and increase accuracy.
A research team from the University of Hong Kong has discovered that the protein FANCM promotes resistance to cancer drugs called PARP inhibitors. This discovery could lead to new treatment strategies and broaden the application of PARP inhibitors across various cancer types.
Researchers from the University of Sheffield have developed a new form of immunotherapy using nanoparticles that delays the onset of resistance to hormone therapy in prostate cancer. This innovative approach stimulates immune cells called T cells to attack cancer cells, marking a significant breakthrough in treating prostate cancer.
Researchers have used cryo-electron microscopy to reveal the structural basis of how cells regulate ferritin, a protein that stores iron. This understanding could lead to the development of drugs that block ferritin's interaction with NCOA4, slowing down aggressive cancer cells.
A new study finds that combining an inhibitor of a metabolic pathway with chemotherapy could improve treatment outcomes in triple negative breast cancer brain metastases. Inhibiting fatty acid synthase, an enzyme critical for cancer cell survival, shows promise in improving chemotherapy efficacy.
Cancer cells can attach themselves to liver cells when specific proteins are present, allowing them to colonize and form new tumors. This discovery provides insights into the metastatic process and may lead to potential treatments that prevent cancer from establishing new tumors.
Researchers studied PTPRK's role in colorectal cancer, finding it acts as a tumour suppressor by regulating cell adhesion and growth factor signalling. The protein also promotes intestinal repair, with mice lacking PTPRK showing impaired wound-healing and increased susceptibility to damage.
Researchers have developed a new technique called burst sine wave electroporation (B-SWE) that can disrupt the blood-brain barrier around brain tumors without causing significant damage to healthy tissue. This method shows promise for treating aggressive brain cancers like glioblastoma, which currently have limited treatment options.
Researchers have designed a novel Co-STAR receptor that combines genetic components of four types of immune cells to recognize and fight cancer cells. In laboratory studies, the Co-STAR receptor induced a sustained anti-tumor response against human cancer cells, leading to long-lasting remissions in mouse models.
Researchers at the University of Notre Dame have developed a wireless LED device that can be implanted to treat deep-seated cancers. The device, combined with a light-sensitive dye, destroys cancer cells and triggers an immune response against them.
A team of Penn State researchers has created a modular genetic circuit that turns cancer cells into a 'Trojan horse,' causing them to self-destruct and kill nearby drug-resistant cancer cells. The circuit outsmarts resistance and eliminates it before the cancer cells can evolve.
Researchers found that bowel cancer cells can regulate their growth using genetic on-off switches, allowing them to maximize survival chances. The study also showed that DNA repair genes can be repeatedly created and repaired, acting as 'genetic switches' to control tumour growth or put the brakes back on.
A new Finnish study from University of Turku shows that already a 30-minute exercise can increase the proportion of tumor-killing white blood cells in the bloodstream of breast cancer patients. The amount of several different white blood cell types increased during exercise, with cytotoxic T cells and natural killer cells rising the most.
Researchers at Karolinska Institutet developed nanorobots that target and kill cancer cells using a 'kill switch' activated in low pH environments. The study achieved a 70% reduction in tumour growth in mice, paving the way for further investigation into its potential as a cancer treatment.
Researchers describe a new concept for an immune response against cancer and aging using senescent cell-derived vaccines. The vaccines aim to stimulate the immune system against cancer cells and slow down or reverse aging-related diseases.
Scientists have developed a new immunotherapy that can identify and fight cancer cells in patients with Merkel cell carcinoma. The treatment involves stimulating the immune system's T cells against specific elements of the virus involved in cancer formation.
Pristimerin selectively targets thioredoxin reductase, inducing apoptosis and inhibiting tumor growth. ROS accumulation triggers oxidative stress, leading to targeted destruction of cancer cells.
Researchers at Howard University have identified a new therapeutic strategy to combat prostate cancer by depleting amino acids. This depletion induces oxidative stress and DNA damage in cancer cells, making them more susceptible to treatment with DNA repair-targeted and immune checkpoint blockade therapies.
A new study found that nearly five percent of pancreatic adenocarcinoma patients achieve a pathological complete response (pCR) after treatment, leading to a 63% 5-year survival rate. The research highlights the importance of tailoring treatment based on factors such as chemotherapy regimens and radiation therapy.
Researchers at Brigham and Women's Hospital have developed a new nanomedicine therapy that delivers anticancer drugs to lung cancer cells and enhances the immune system's ability to fight cancer. The therapy shows promising results in cancer cells in the lab and in mouse lung tumor models, with potential applications for improving care...
Researchers found that metformin increases levels of microRNAs miR-2110 and miR-132-3p, targeting genes PIK3R3 and STMN1 to slow down cancer cell growth and division. This study provides new insights into metformin's molecular mechanisms and its potential as a preventive agent for reducing cancer growth.
The study reveals that the binding sites of USP28 and USP25 inhibitors are identical, leading to non-specific effects. Researchers now aim to develop precise inhibitors targeting either enzyme site to reduce side effects.
A team of researchers from Xi'an Jiaotong-Liverpool University has engineered a short sequence of artificial DNA to target the mutant protein p53-R175H, linked to lung, colorectal, and breast cancers. The new molecule, dp53m, inhibits cancer cell growth and increases sensitivity to chemotherapy agent cisplatin.
Researchers at The Hebrew University have developed a novel method combining nano informatics and machine learning to predict cancer cell behaviors with high accuracy. This innovative approach enables the rapid identification of cancer cell subpopulations with varying biological behaviors, facilitating personalized medicine.
Researchers at MUSC Hollings Cancer Center discover polyploid giant cancer cells can lead to disease recurrence after chemotherapy or radiotherapy. They found that targeting these 'monster cells' could prevent tumor relapse, and potential therapies like tamoxifen and statins may also be effective.
Researchers at Hollings Cancer Center have identified a promising therapeutic strategy to combat pancreatic cancer. By simultaneously blocking HSP70 and autophagy, the growth of pancreatic tumors can be slowed, offering new hope for treatment.
A study by Charité researchers found that yeast cells can compensate for aneuploidy by exchanging proteins faster. This mechanism could be used to tackle treatment-resistant tumors and fungal infections. The study identified a previously unknown compensation system based on Saccharomyces cerevisiae.
A study found that moderate-to-vigorous exercise bouts increased natural killer cells' ability to kill cancer cells and made them more susceptible to antibody therapy. This could hold promise for improving treatment outcomes for some forms of chronic lymphocytic leukemia. Further research is needed to confirm these findings.